Clinical Trials in Winterthur, Switzerland
2 recruiting
Showing 1–20 of 20 trials
Recruiting
Phase 3
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
ETOP IBCSG Partners Foundation390 enrolled34 locationsNCT06931717
Recruiting
Phase 3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ETOP IBCSG Partners Foundation290 enrolled42 locationsNCT06284317
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Renal Cell Carcinoma (RCC)
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 2
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Non-small Cell Lung Cancer
AstraZeneca180 enrolled77 locationsNCT06448754
Recruiting
Phase 2
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
SCLC,Extensive StageSLFN11-positive
ETOP IBCSG Partners Foundation44 enrolled18 locationsNCT05718323
Recruiting
Not Applicable
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Breast Cancer
University Hospital, Basel, Switzerland1,060 enrolled36 locationsNCT07140172
Recruiting
Phase 2
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Breast Cancer
Swiss Cancer Institute50 enrolled8 locationsNCT06452394
Recruiting
Phase 3
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation180 enrolled15 locationsNCT05522660
Recruiting
Not Applicable
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
Lymphedema, Breast Cancer
University Hospital, Basel, Switzerland280 enrolled35 locationsNCT05890677
Recruiting
Phase 2
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Swiss Cancer Institute54 enrolled9 locationsNCT06358573
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
Hereditary Breast and Ovarian CancerLynch Syndrome
University of Basel700 enrolled9 locationsNCT03124212
Recruiting
Not Applicable
The DIALOGUE Study: Swiss-Korean Billateral Collaboration
Breast CancerOvarian CancerHereditary Cancer
University of Basel228 enrolled8 locationsNCT04214210
Recruiting
Not Applicable
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
Node-positive Breast Cancer
University Hospital, Basel, Switzerland1,500 enrolled67 locationsNCT03513614
Recruiting
Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
CarcinomaNon-Small-Cell Lung
AstraZeneca324 enrolled283 locationsNCT05261399
Recruiting
Not Applicable
Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer
Breast Cancer
Klinik Hirslanden, Zurich420 enrolled26 locationsNCT04289935